Converting HR+ Breast Cancer Into an Individualized Vaccine
Public ClinicalTrials.gov record NCT03804944. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Newly diagnosed post-menopausal women with clinical stage II-III, HR+HER2- breast cancer are eligible to a randomized trial, concurrently open at five US academic institutions. Patients receiving 4 months of standard neoadjuvant hormonal therapy with letrozole are randomly assigned to one of 4 arms of a trial testing focal hypo-fractionated RT alone or with immunotherapy combinations.
Study identification
- NCT ID
- NCT03804944
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 100 participants
Conditions and interventions
Conditions
Interventions
- Focal Radiation therapy Radiation
- Pembrolizumab (200mg IV for 30 minutes Drug
- CDX-301 Biological
Radiation · Drug · Biological
Eligibility (public fields only)
- Age range
- 18 Years to 90 Years
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 16, 2020
- Primary completion
- Dec 30, 2026
- Completion
- Dec 30, 2027
- Last update posted
- Jan 27, 2026
2020 – 2027
United States locations
- U.S. sites
- 8
- U.S. states
- 4
- U.S. cities
- 5
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Cedars-Sinai Medical Center | Los Angeles | California | 90048 | Withdrawn |
| Icahn School of Medicine at Mt Sinai | New York | New York | 10027 | Withdrawn |
| New York Presbyterian Hospital - Queens | New York | New York | 10065 | Recruiting |
| Weill Cornell Medicine New York Presbyterian Hospital | New York | New York | 10065 | Recruiting |
| Brooklyn Methodist Hospital - NewYork Presbyterian | New York | New York | 11215 | Recruiting |
| UPMC Hillman Cancer Center | Pittsburgh | Pennsylvania | 15232 | Withdrawn |
| UT Southwestern Medical Center | Dallas | Texas | 75390-9179 | Recruiting |
| Houston Methodist Cancer Center | Houston | Texas | 77030 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03804944, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 27, 2026 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03804944 live on ClinicalTrials.gov.